At present, RITUXIMAB, a chimeric monoclonal antibody directed against the CD20, combined with intensive chemotherapy (CHOP) is the standard therapy for DLBCL (Figure 6D). Here, MS4A1 is linked to diffuse large B-cell lymphoma.